News

News

October 19th, 2020

PEP-Therapy has been selected by Doorway, the first online equity investing platform authorized by Consob. Doorway is a new alternative finance hub, unique in Italy, for raising equity capital and debt financing for startups and validated SMEs, and for investors’ access and real economy investments.

Invest together with Business Angel networks!

The project will be online until November 30th.

 

October 6th, 2020

PEP-Therapy announces the appointments in its Scientific Advisory Board (SAB) of four experts in oncology and peptide development: Pr. Isabelle Ray-Coquard, MD, PhD, Pr. Mario Campone, MD, PhD, Pr. Jean Martinez, PhD, and Dr. Bruno Giroux, MD, PharmD.

The full announcement is available here.

 

October 2nd, 2019

PEP-Therapy is proud to be part of the laureates of ReAliZe, the open innovation program of AstraZeneca in oncology.

 

May 16th, 2019

PEP-Therapy announces that its first-in-class drug candidate, PEP-010, successfully completed Good Laboratory Practice (GLP) toxicity study, moving towards its first-in-human clinical trial.

The full press release is available here (and French version here).

Here is an article from BiotechFinances (in French).

 

April 17th, 2018

PEP-Therapy, Institut Curie and Gustave Roussy join together to conduct the Clever-Peptide project.

It aims at the development of an innovative anti-cancer peptide, firstly for the treatment of triple-negative breast cancer, and its companion biomarker, predictive of treatment efficacy. Approved by the Medicen Paris Region cluster, this collaborative project obtains 2,9 M€ funding.

The press release is available here (French version here).

 

March 27th, 2018

PEP-Therapy announces the presentation of preclinical data on the PEP-010 drug candidate at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place from April 14 to 18 in Chicago, USA.

More details are available here.

 

November 16th, 2017

PEP-Therapy raises €1.2 million.

The company continues the development of its portfolio of drug candidates

and of their companion biomarkers in oncology.

The full press release is available here.

 

May 23rd, 2017

PEP-Therapy took part in the 18th annual Bio€quity Europe on May 22nd and 23rd in Paris.

Bio€quity is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.

 

 

May 12th, 2017

PEP-Therapy took part in the 3rd edition of the MEET2WIN business convention organized by MATWIN in Bordeaux on May 11th and 12th, dedicated to open innovation, collaborative research and technology transfer in oncology.

PEP-Therapy was awarded a prize as one of the 2 best pitch presentations.

 

 

December 13th, 2016

PEP-Therapy was proud to take part in "The Investment Plan for Europe: delivering results" seminar at the European Commission on November 29th. One major pillar of the Plan is the European Fund for Strategic Investments (EFSI).

PEP-Therapy is one of the approved EFSI project. The company received €1 million support from Quadrivium 1, a French investment fund that received a €20 million injection from the European Investment Fund (EIF).

Both partners are featured on the European Commission and EIF websites.

 

 

October 28th, 2016

PEP-Therapy took part in the 3rd edition of the MedStartUp days at the Alexandria Center For Life Science in New York.

MedStartUp, organized by the Galien Foundation and Business France, bring together highly innovative French companies in the healthcare industry and American leaders in the pharma, medtech and digital health industries, to encourage and reward new transatlantic partnerships.

 

July 9th, 2016

PEP-Therapy and partners have been awarded a European H2020 grant to fight eye cancer for the next 5 years. Under the coordination of Institut Curie, UM Cure 2020 is a new European consortium involving 12 partners to foster research on metastatic uveal melanoma (UM), a rare disease.

UM Cure 2020 has received €6 million of funding to develop new therapeutic approaches to treat metastatic UM.

The full press release is available here.

April 7th, 2016

PEP-Therapy is ranked among the French 100 top start-ups to invest in by Challenges business magazine.

A few days later, Challenges provides a portrait of PEP-Therapy.

November 20th, 2015

PEP-Therapy was part of the four finalists to compete for the 2015 Academic Enterprise Awards (ACES). The finalists presented their venture at the 2015 Science|Business annual summit in Barcelona, where leaders from research, industry and policy have debated how best unleash Europe’s technological potential.

For further information about ACES and the finalists, click here.

 

November 3rd, 2015

PEP-Therapy is very pleased to be profiled in this week BioCentury issue.

The article is available here.

 

June 23rd, 2015

PEP-Therapy is now a member of Medicen Paris Region.

April 27th, 2015

PEP-Therapy raises €1.3 million in seed capital.

The company is undertaking development of its first drug candidate and its companion diagnostic in oncology.

The full press release is available here (French version available here).

 

BiotechFinances is talking about it. Read the article.

February 20th, 2015

The final of the 15th edition of Tremplin Entreprises competition took place at the French Senate on Monday, February 9th. PEP-Therapy is part of the 9 award winners in the life sciences category.

For further information concerning the winners, click here.

The full press release is available here.

© PEP-Therapy 2014-2020